Skip to main content

Table 1 Clinical trials of PARP inhibitor drugs for pancreatic cancer

From: PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications

Trial IDTherapeutic DrugsPhaseStatusTreatment SettingPrimary Outcomes
NCT02677038OlaparibIIRecruitingMetastatic PAC
Patients must be germline BRCA 1 or 2 negative
Objective tumor response rate
NCT02511223OlaparibIIUnknownMetastatic PAC with BRCA 1/2 mutations negative but loss of ATMObjective response rate
NCT01078662OlaparibIIActive, not recruitingAdvanced tumors with BRCA1/2 mutation, including pancreatic cancerTumor response rate
NCT02184195Olaparib
Placebo
IIIActive, not recruitingMetastatic adenocarcinoma of the pancreas with germline BRCA1/2 mutationsProgression-free survival
NCT01296763Olaparib
Irinotecan
Cisplatin Mitomycin-C
ICompletedAdvanced pancreatic cancerMaximum-tolerated dose
NCT00515866KU-0059436
(AZD2281)
Gemcitabine
ICompletedAdvanced or metastatic
unresectable PAC
Maximum-tolerated dose
or tolerable and effective dose
NCT03682289Olaparib
ATR Kinase Inhibitor AZD6738
IIRecruitingLocally advanced or metastatic solid tumor malignancy, including
pancreatic cancer
Objective response rate
NCT03851614Olaparib
Cediranib
IIRecruitingMismatch repair-proficient colorectal cancer
Pancreatic adenocarcinoma
Leiomyosarcoma
Genomic and immune biomarkers
NCT02498613Olaparib
Cediranib Maleate
IIRecruitingMetastatic or unresectable malignancy, including PDACObjective response rate
NCT03878524SMMART Therapy
Including Olaparib
INot yet recruitingBreast cancer
Prostate cancer
Pancreatic cancer
Acute myelogenous leukemia
The number of participants to complete first dose of first SMMART therapy
NCT00892736VeliparibICompletedSolid tumors with BRCA1/2 mutations, including pancreatic cancerMaximum-tolerated dose
Dose-limiting toxicities
Recommended phase II dose
NCT01908478Veliparib
Gemcitabine
IActive, not recruitingPancreatic cancerMaximum-tolerated dose
NCT01489865ABT-888
mFOLFOX-6
I and IIActive, not recruitingMetastatic pancreatic cancerDose-limiting toxicities
NCT02890355Veliparib
Fluorouracil
Irinotecan Hydrochloride
Leucovorin Calcium
IIActive, not recruitingMetastatic pancreatic adenocarcinoma,
recurrent pancreatic
carcinoma, stage IV
pancreatic cancer
Overall survival
NCT01585805Veliparib
Cisplatin
Gemcitabine
Gemcitabine Hydrochloride
IIActive, not recruitingLocally advanced or metastatic pancreas adenocarcinoma with a BRCA1/2 or PALB2 mutationOptimal dose
Response rate
NCT01282333Veliparib
Cisplatin
Gemcitabine Hydrochloride
ITerminatedAdvanced biliary/pancreatic cancer, urothelial cancer, non-small cell lung cancerMaximum-tolerated dose
NCT02831179Veliparib
Capecitabine
Temozolomide
IWithdrawnMetastatic unresectable neuroendocrine tumors, non-functional pancreatic neuroendocrine tumors,
pancreatic glucagonoma, pancreatic insulinoma
Maximum-tolerated dose
NCT01233505Veliparib
Capecitabine
Oxaliplatin
ITerminatedBRCA-related solid tumors, including
pancreatic cancer
Dose-limiting toxicities
Maximum-tolerated dose
NCT00576654Veliparib
Irinotecan Hydrochloride
IActive, not recruitingMalignant solid neoplasms,
including pancreatic cancer
Optimal biologic dose
NCT03140670RucaparibIIRecruitingLocally advanced or metastatic
pancreatic cancer
Number of adverse events
NCT02042378RucaparibIICompletedPancreatic cancer, pancreatic ductal adenocarcinomaOverall response rate
NCT03337087Rucaparib
Fluorouracil
Leucovorin Calcium
Liposomal Irinotecan
I and IIRecruitingPancreatic, colorectal, gastroesophageal or biliary adenocarcinomaMaximum-tolerated dose
NCT02711137Rucaparib
INCB057643
Gemcitabine
Paclitaxel
Abiraterone
Ruxolitinib
Azacitidine
I and IITerminatedSolid tumors, including pancreatic cancerSafety and tolerability
NCT01286987TalazoparibICompletedLocally advanced or metastatic solid tumors, including pancreatic cancerNumber of participants with an objective response
NCT02567396TalazoparibIWithdrawnMetastatic or unresectable malignancies including pancreatic adenocarcinomaIncidence of toxicity
Recommended phase 2 dose
Tolerability
NCT03637491Talazoparib
Avelumab
Binimetinib
IIRecruitingLocally advanced or metastatic solid tumors, pancreatic cancerDose-limiting toxicity
NCT03601923NiraparibIIRecruitingPancreatic cancerProgression-free survival
NCT03553004NiraparibIIRecruitingPancreatic cancerObjective response rate
NCT03404960Niraparib + Nivolumab
Niraparib + Ipilimumab
I and IIRecruitingPancreatic adenocarcinomaProgression-free survival
NCT02244489Momelotinib
Capecitabine
Oxaliplatin
ITerminatedRelapsed/refractory metastatic pancreatic ductal adenocarcinomaIncidence of dose-limiting toxicities
Safety
NCT02101021Momelotinib
Placebo to match Momelotinib
Nab-paclitaxel
Gemcitabine
IIITerminatedMetastatic pancreatic ductal adenocarcinomaDose-limiting toxicity
Overall survival